Zura Bio Q2 2025 net loss $16.0M; cash $154.5M funds through 2027

Zura Bio Ltd

2025-Q2 EPS reported -$0.36

Cash and cash equivalents of $154.5M as of June 30, 2025, expected to fund operations through 2027.
Q2 2025 net loss of $16.0M ($0.17 per share) vs $10.3M ($0.17 per share) in Q2 2024.
R&D expenses rose to $8.7M (up $3.2M YoY) driven by Phase 2 studies for tibulizumab in SSc and HS.
Initiated TibuSHIELD Phase 2 for hidradenitis suppurativa; topline data expected Q3 2026.
Appointed Eric Hyllengren as CFO (July 2025) and Dan Becker, M.D., Ph.D. to Board (May 2025).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.